Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 31st total of 76,200 shares. Based on an average daily trading volume, of 787,700 shares, the short-interest ratio is presently 0.0 days.
Astellas Pharma Trading Down 0.6 %
Shares of Astellas Pharma stock opened at $9.78 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The business has a fifty day simple moving average of $9.89 and a two-hundred day simple moving average of $10.99. Astellas Pharma has a 1 year low of $9.05 and a 1 year high of $13.14. The company has a market capitalization of $17.70 billion, a price-to-earnings ratio of 46.57 and a beta of 0.34.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.40%. The company had revenue of $3.11 billion during the quarter. Research analysts forecast that Astellas Pharma will post 0.61 EPS for the current year.
Astellas Pharma Company Profile
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
- Five stocks we like better than Astellas Pharma
- What is the Euro STOXX 50 Index?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Steel Stocks Soaring After Tariff Announcements
- How Can Investors Benefit From After-Hours Trading
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.